semaglutide tablets patent expiry Generic opens over Rs 50,000 Crore opportunity for drugmakers: Report Zydus launches Semaglutide Injection in

The difference between "working as intended" and "needing medical attention" isn't always clear

The nasal mucosa offers a direct pathway to systemic circulation, bypassing first-pass metabolism entirely

Increased Galectin-9 expression activates CD47 signaling, which inhibits immune cell phagocytosis of damaged or ferroptotic cells

BENEFITS Triple receptor activation studied for simultaneous GLP-1, GIP, and glucagon engagement Metabolic research explored in Phase 2 clinical trials with notable body-composition results Glucagon component linked to thermogenesis and energy-expenditure pathways Next-generation compound investigated as an advancement over dual-agonist approaches Comparative pharmacology assessed alongside mono- and dual-agonists in research settings WHAT RESEARCHERS LOOK AT Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors Additive effects of glucagon-receptor activation on energy expenditure Dose-response and tolerability profiling from clinical-trial data Comparative outcomes vs tirzepatide and semaglutide Pharmacokinetic profiling and receptor selectivity